Novo Nordisk’s semaglutide franchise has taken off in a big way. Type 2 diabetes med Ozempic smashed the blockbuster barrier in 2019, the same year the company launched its oral option, Rybelsus. Now, the Danish diabetes major is touting data on a higher-dose prospect. In a late-stage trial, Ozempic 2 mg trumped its 1-mg predecessor on blood… Read More »
The COVID-19 pandemic derailed plans for companies worldwide last year, but Eli Lilly adapted by developing medicines against the novel coronavirus—to the tune of $ 871 million in antibody revenue for Q4—while still pushing sales of its newer meds. Now, CEO David Ricks is reaping the rewards with a pay package that could place him… Read More »
Bayer’s for-sale animal health unit has been stirring up interest among private equity players—but the German pharma may have another buyer in mind. The company has approached Elanco, spun off by Eli Lilly last year, about a potential tie-up between the two, Reuters reports, citing three unnamed sources. Elanco currently holds the animal health market’s… Read More »